Asthma treatment

http://www.healasthma.com past six monthsthe past twelve months Search Hint Connecting terms with OR broadens your search to give more results …more on search operators – . FD (FAIR DISCLOSURE) WIRE – Q Sepracor Earnings Conference Call – Final OPERATOR Welcome to Sepracor’s fourth-quarter and full-year earnings conference call. Hosting the call today from Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. (OPERATOR INSTRUCTIONS) It is now my pleasure to turn the floor over to your host, Mr. Adrian Adams. Sir, you begin.ADRIAN ADAMS, PRESIDENT… . Inside Surgery – Oct. , ( Inside Surgery delivered by Newstex) — Scheduled Nebulizer Treatment in Paraplegics Most physiatrists (rehab physicians) put patients with high spinal cord injuries on a scheduled regimen of nebulizer treatment to facilitate clearance of secretions. These patients tend to have hyperactivity of the airway and the unopposed parasympathetic stimulation of albuterol stimulates increased ciliary function. Copyright … . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Mannix, Teva Pharmaceutical Industries Ltd., Investor Relations . Shlomo Yanai, Teva Pharmaceutical Industries Ltd., President & CEO . George Barrett, Teva Pharmaceutical Industries Ltd., Corporate EVP, Global Pharmaceutical Markets and President & CEO – Teva North America . Dan Suesskind, Teva Pharmaceutical Industries Ltd., CFO . David Buck, Buckingham Research Group, Analyst . Rich Silver, Lehman Brothers, Analyst . Corey… . FD (FAIR DISCLOSURE) WIRE – Q Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Greetings, ladies and gentlemen, and welcome to the Teva Pharmaceutical Industries Ltd. second quarter results conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded. It is my pleasure to introduce your host, Mr. Kevin Mannix. Thank you, you begin. KEVIN MANNIX, INVESTOR RELATIONS, TEVA PHARMACEUTICAL… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Mannix, Teva Pharmaceutical Industries Ltd., Investor Relations . Shlomo Yanai, Teva Pharmaceutical Industries Ltd., President & CEO . George Barrett, Teva Pharmaceutical Industries Ltd., Corporate EVP, Global Pharmaceutical Markets and President & CEO – Teva North America . Dan Suesskind, Teva Pharmaceutical Industries Ltd., CFO . David Buck, Buckingham Research Group, Analyst . Rich Silver, Lehman Brothers, Analyst . Corey… . FD (FAIR DISCLOSURE) WIRE – Q Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Greetings, ladies and gentlemen, and welcome to the Teva Pharmaceutical Industries Ltd. second quarter results conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded. It is my pleasure to introduce your host, Mr. Kevin Mannix. Thank you, you begin. KEVIN MANNIX, INVESTOR RELATIONS, TEVA PHARMACEUTICAL… . FD (FAIR DISCLOSURE) WIRE – Sepracor at Cowen and Company Annual Health Care Conference – Final JONAE BARNES, VP, INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS, SEPRACOR Hi, everybody. Thank you for coming today to see the presentation. My name is Jonae Barnes, and I’m the Vice President of Investor Relations and Corporate Communications of Sepracor. Here’s our forward-looking statement. I’m sure everybody is familiar with them, so I’m not going to pain you and read through it.Sepracor is one of only a few companies outside of… . FD (FAIR DISCLOSURE) WIRE – Sepracor at Cowen and Company Annual Health Care Conference – Final JONAE BARNES, VP, INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS, SEPRACOR Hi, everybody. Thank you for coming today to see the presentation. My name is Jonae Barnes, and I’m the Vice President of Investor Relations and Corporate Communications of Sepracor. Here’s our forward-looking statement. I’m sure everybody is familiar with them, so I’m not going to pain you and read through it.Sepracor is one of only a few companies outside of… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Q Ivax Earnings Conference Call – Final CORPORATE PARTICIPANTS . Phillip Frost, IVAX Corporation., Chairman & CEO . Neil Flanzraich, IVAX Corporation., Vice Chairman & President . Tom Beier, IVAX Corporation., SVP – Finance & CFO . David Malina, IVAX Corporation., Director – IR OVERVIEW IVX reported Q net revenues of m, gross profit of . m, increases of % and % respectively over comparable figures for Q . IVX’s US generic business was a major… . FD (FAIR DISCLOSURE) WIRE – Q Ivax Earnings Conference Call – Final OPERATOR Ladies and gentlemen, thank you for standing by. Welcome to the second-quarter earnings conference call. At this time, all participants are in a listen-only mode. (OPERATOR INSTRUCTIONS). As a reminder, our conference is being recorded today. I would now like to turn the conference over to our host, Chief Executive Officer of IVAX, Dr. Phillip Frost.DR. PHILLIP FROST, CHAIRMAN & CEO, IVAX CORPORATION Good morning, everyone. I’m Phillip Frost,… –